A Phase 1 interventional study of Pirtobrutinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-13.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to compare two different formulations (mixtures) of pirtobrutinib (LOXO-305) in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will be collected. The study will last up to 65 days.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History or presence of any of the following, deemed by the Investigator (or designee), and/or Sponsor:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Participants received a reference formulation (R) of oral pirtobrutinib 200 milligrams (mg) on day 1. Period 2: Participants received a test formulation (T) of oral pirtobrutinib 200 mg on day 8. There was a washout period of 7 days between the doses of pirtobrutinib.
Drug: Pirtobrutinib
Period 1: Participants received a test formulation (T) of oral pirtobrutinib 200 mg on day 1. Period 2: Participants received a reference formulation (R) of oral pirtobrutinib 200 mg on day 8. There was a washout period of 7 days between the doses of pirtobrutinib.
Drug: Pirtobrutinib
Administered orally.
Also known as: LOXO-305, LY3527727
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib
PK: AUC0-24 of Pirtobrutinib
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
PK: AUC0-t of Pirtobrutinib
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib
PK: AUC0-inf of Pirtobrutinib
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib
PK: %AUCextrap of Pirtobrutinib
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib
PK: CL/F of Pirtobrutinib
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib
PK: t1/2 of Pirtobrutinib
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib
PK: Cmax of Pirtobrutinib
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
PK: Tmax of Pirtobrutinib
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib
PK: λZ of Pirtobrutinib
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Pirtobrutinib
PK: Vz/F of Pirtobrutinib
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Participants were randomized to 2 treatment sequences (R/T, T/R), with each sequence having 2 periods where participants were crossed over between the periods. A washout period of 7 days was maintained between doses of each treatment period.
| Milestone | 200 mg Pirtobrutinib (Sequence R/T) | 200 mg Pirtobrutinib (Sequence T/R) |
|---|---|---|
| Started | 14 | 14 |
| Received at least 1 dose of study drug | 14 | 14 |
| Completed | 14 | 14 |
| Not completed | 0 | 0 |
| Milestone | 200 mg Pirtobrutinib (Sequence R/T) | 200 mg Pirtobrutinib (Sequence T/R) |
|---|---|---|
| Started | 14 | 14 |
| Received at least 1 dose of study drug | 14 | 14 |
| Completed | 14 | 14 |
| Not completed | 0 | 0 |
PK: AUC0-24 of Pirtobrutinib
| hour*nanogram per milliliter (h*ng/mL) | 200 mg Pirtobrutinib (Reference Formulation) | 200 mg Pirtobrutinib (Test Formulation) |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib | 48800 ± 29.1 | 49700 ± 20.6 |
PK: AUC0-t of Pirtobrutinib
| hour*nanogram per milliliter (h*ng/mL) | 200 mg Pirtobrutinib (Reference Formulation) | 200 mg Pirtobrutinib (Test Formulation) |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib | 81100 ± 36 | 83600 ± 24.7 |
PK: AUC0-inf of Pirtobrutinib
| hour*nanogram per milliliter (h*ng/mL) | 200 mg Pirtobrutinib (Reference Formulation) | 200 mg Pirtobrutinib (Test Formulation) |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib | 82000 ± 35.5 | 84700 ± 24.4 |
PK: %AUCextrap of Pirtobrutinib
| percentage of AUCextrap | 200 mg Pirtobrutinib (Reference Formulation) | 200 mg Pirtobrutinib (Test Formulation) |
|---|---|---|
| PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib | 1.01 ± 46.9 | 1.12 ± 36.7 |
PK: CL/F of Pirtobrutinib
| liter per hour (L/h) | 200 mg Pirtobrutinib (Reference Formulation) | 200 mg Pirtobrutinib (Test Formulation) |
|---|---|---|
| PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib | 2.44 ± 35.5 | 2.36 ± 24.4 |
PK: t1/2 of Pirtobrutinib
| hours | 200 mg Pirtobrutinib (Reference Formulation) | 200 mg Pirtobrutinib (Test Formulation) |
|---|---|---|
| PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib | 18.9 ± 21.2 | 19 ± 20.3 |
PK: Cmax of Pirtobrutinib
| nanogram per milliliter (ng/mL) | 200 mg Pirtobrutinib (Reference Formulation) | 200 mg Pirtobrutinib (Test Formulation) |
|---|---|---|
| PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib | 3960 ± 23.3 | 3980 ± 24.2 |
PK: Tmax of Pirtobrutinib
| hours | 200 mg Pirtobrutinib (Reference Formulation) | 200 mg Pirtobrutinib (Test Formulation) |
|---|---|---|
| PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib | 2.50 (0.500 to 6) | 2.50 (0.750 to 6) |
PK: λZ of Pirtobrutinib
| 1/hour (1/h) | 200 mg Pirtobrutinib (Reference Formulation) | 200 mg Pirtobrutinib (Test Formulation) |
|---|---|---|
| Subject 1 | 0.0487 | 0.0347 |
| Subject 2 | 0.0420 | 0.0374 |
| Subject 3 | 0.0549 | 0.0563 |
| Subject 4 | 0.0446 | 0.0386 |
| Subject 5 | 0.0406 | 0.0382 |
| Subject 6 | 0.0382 | 0.0389 |
| Subject 7 | 0.0355 | 0.0348 |
| Subject 8 | 0.0335 | 0.0341 |
| Subject 9 | 0.0414 | 0.0390 |
| Subject 10 | 0.0431 | 0.0437 |
| Subject 11 | 0.0358 | 0.0321 |
| Subject 12 | 0.0432 | 0.0427 |
| Subject 13 | 0.0324 | 0.0382 |
| Subject 14 | 0.0198 | 0.0179 |
| Subject 15 | 0.0409 | 0.0371 |
| Subject 16 | 0.0457 | 0.0451 |
| Subject 17 | 0.0279 | 0.0284 |
| Subject 18 | 0.0305 | 0.0299 |
| Subject 19 | 0.0407 | 0.0478 |
| Subject 20 | 0.0290 | 0.0350 |
| Subject 21 | 0.0293 | 0.0342 |
| Subject 22 | 0.0408 | 0.0403 |
| Subject 23 | 0.0340 | 0.0322 |
| Subject 24 | 0.0269 | 0.0299 |
| Subject 25 | 0.0372 | 0.0379 |
| Subject 26 | 0.0359 | 0.0396 |
| Subject 27 | 0.0370 | 0.0369 |
| Subject 28 | 0.0360 | 0.0368 |
PK: Vz/F of Pirtobrutinib
| Liter (L) | 200 mg Pirtobrutinib (Reference Formulation) | 200 mg Pirtobrutinib (Test Formulation) |
|---|---|---|
| PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Pirtobrutinib | 66.6 ± 36.7 | 64.9 ± 28.4 |
Collected over Baseline to Follow-up (Up To Day 24). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 mg Pirtobrutinib (Reference Formulation) | 0/28 (0%) | 0/28 (0%) | 0/28 (0%) |
| 200 mg Pirtobrutinib (Test Formulation) | 0/28 (0%) | 0/28 (0%) | 1/28 (3.6%) |
| Event | 200 mg Pirtobrutinib (Reference Formulation) | 200 mg Pirtobrutinib (Test Formulation) |
|---|---|---|
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/28 | 1/28 |
All randomized participants.
| Age, Continuous(years) | 200 mg Pirtobrutinib (Sequence R/T) | 200 mg Pirtobrutinib (Sequence T/R) | Total |
|---|---|---|---|
| Mean | 40.2 ± 6.860 | 33.5 ± 9.940 | 36.9 ± 9.050 |
| Sex: Female, Male(Participants) | 200 mg Pirtobrutinib (Sequence R/T) | 200 mg Pirtobrutinib (Sequence T/R) | Total |
|---|---|---|---|
| Female | 2 | 1 | 3 |
| Male | 12 | 13 | 25 |
| Ethnicity (NIH/OMB)(Participants) | 200 mg Pirtobrutinib (Sequence R/T) | 200 mg Pirtobrutinib (Sequence T/R) | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 11 | 12 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 200 mg Pirtobrutinib (Sequence R/T) | 200 mg Pirtobrutinib (Sequence T/R) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 3 | 8 |
| White | 6 | 8 | 14 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 200 mg Pirtobrutinib (Sequence R/T) | 200 mg Pirtobrutinib (Sequence T/R) | Total |
|---|---|---|---|
| United States | 14 | 14 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Dec 2021, 2 months.
Results were first posted in Jan 2025, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib